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Abstract
Multidrug resistance is a major obstacle in successful
systemic therapy of gynecologic malignancies. The ob-
jectives of this study are to evaluate the activity of
cyclosporin A used to overcome drug resistance in a
(variety of gynecologic malignancies. Forty women 29
with ovarian cancer, 7 with uterine cancer, 3 with cervi-
)cal cancer, and 1 with choriocarcinoma were treated
with cyclosporin A, 4 mg/kg intravenously, 6 hours
before and 18 hours after the specific chemotherapeu-
tic agent, to which the tumor had developed drug resis-
tance. All patients had shown resistance to the chemo-
therapy agent used in combination with cyclosporin A.
(All patients had been heavily pretreated mean, 2.8
)previous chemotherapy regimens . Overall, among 38
available patients with gynecologic malignancies, a 29%
( )objective response rate was observed. Twenty-six 65%
of all patients received three or more cycles of cy-
closporin A. There was a 25% response rate for patients
with ovarian cancer patients and 50% for those with
uterine cancer. There were no responses among the
three patients with cervical cancer, and the patient with
choriocarcinoma had a complete response. All patients
were evaluable for toxicity. Leukopenia and nausea were
the most common toxic reactions, but in most cases
they were transient, and only three patients required a
treatment delay. The most common grade 3 or 4 toxicity
was thrombocytopenia, which was observed in 22% of
the patients. Cyclosporin A is well tolerated and has
significant potential for reversal of chemoresistance in
heavily pretreated patients with ovarian and uterine
malignancies.
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Introduction
Despite advances in combination chemotherapy, the suc-
cessful management of advanced or recurrent gynecologic
malignancies is often difficult due to both intrinsic and ac-
quired resistance of cancer cells to chemotherapeutic
agents. Even in ovarian cancer, which routinely shows ap-
parent complete response to chemotherapy, regrowth of
resistant cancer cells is a major hindrance to improvement
in progression-free interval and long-term survival. Several
mechanisms of drug resistance have been proposed, includ-
( )ing multidrug resistance MDR , detoxification of potentially
cytotoxic metabolites, and enhanced DNA repair. Although
several mechanisms may be involved simultaneously, a
significant proportion of drug resistance is attributed to am-
[ ]plification of the MDR gene 1 . The MDR gene is known to
code for a membrane-associated protein that acts as an
( )adenosine triphosphate ATP –dependent efflux pump to
transport the chemotherapeutic agents out of the cell.
Recent in vitro studies have revealed several agents that
can down-regulate MDR function and enhance response to
cytotoxic agents. These modifiers of MDR function include
calcium channel blockers, calmodulin inhibitors, quinidine,
[ ]tamoxifen, and cyclosporin A 2 . Cyclosporin A is an im-
munosuppressive cyclic polypeptide with unique pharmaco-
dynamic properties. It interferes with T-cell growth and dif-
ferentiation by inhibiting production of interleukin-2 at the
[ ]transcriptional level 3 . Previous studies with cyclosporin A
have shown in vitro and in vivo reversal of chemoresis-
tance to compounds associated with MDR elevation in the
resistance mechanism. Such compounds include etoposide,
[ ]vincristine, doxorubicin, and daunorubicin 1,4–8 . Cy-
closporin A has also been shown to reverse resistance to
cisplatin unrelated to MDR gene amplification. The maxi-
mum tolerated dose, as well as the pharmacokinetics of
[ ]cyclosporin A, have been reported 9–11 . In an attempt to
overcome drug resistance we evaluated response rates,
duration of response, and toxicity with a variety of agents in
heavily pretreated patients with gynecologic malignancies.
Materials and Methods
All patients with advanced gynecologic malignancies who
were treated with cyclosporin A at the University of Iowa
Hospitals and Clinics between July 1, 1993, and December
31, 1996, were identified through the Department of Phar-
maceutical Care comprehensive database and the Univer-
sity of Iowa Tumor Registry. Forty women were identified,
and all charts were available for review. Records were
retrospectively reviewed with particular attention to the initial
history and physical examination, histopathologic findings,
operative and postoperative treatment including chemo-
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therapy, and follow-up. Diagnosis was verified by pathology
review at the institutional Gynecologic Oncology Tumor
Board. All patients were staged according to the Interna-
( )tional Federation of Gynecology and Obstetrics FIGO stag-
ing system. Complete follow-up was available for all pa-
tients.
All patients treated with cyclosporin A were heavily pre-
treated with multiple chemotherapy regimens, and all had
demonstrated chemoresistance to the specific agent used in
combination with cyclosporin A. Resistance to a chemother-
apeutic agent was defined as disease progression during
treatment with the agent or recurrence within 6 months of
[ ]previous therapy 12 . Cyclosporin A, 4 mg/kg, was admin-
istered intravenously 6 hours before and 18 hours after the
specific chemotherapeutic agent. This dose was derived
from the phase I trial conducted by the Gynecologic Oncol-
( ) [ ]ogy Group GOG 9 . Treatment was repeated every 21
days until disease progressed or unacceptable toxicity de-
veloped.
Before each cycle of chemotherapy, a complete blood
count with differential, platelet count, serum electrolytes,
liver function tests, and serum creatinine was obtained on
each patient. Serum CA 125 levels were also obtained
before each cycle of chemotherapy in patients with ovarian
cancer. Antiemetic regimens usually consisted of on-
dansetron and dexamethasone surrounding the infusion of
platinum, and dexamethasone and metoclopramide for 3
days after platinum infusion. All toxicity was graded accord-
[ ]ing to the GOG criteria 13 . Granulocyte colony stimulating
( )factor G-CSF was administered in accordance with the
( )American Society of Clinical Oncology ASCO guidelines
[ ]14 .
Patients were evaluated for response before each course
of chemotherapy. Only patients with measurable disease
and/or CA 125 levels were considered evaluable for as-
sessing response to chemotherapy. In patients with measur-
( )able disease, complete response CR represented disap-
pearance of clinical evidence of all disease, and partial
( )response PR denoted a decrease of at least 50% in the
tumor volume. Progression denoted a 25% or more in-
crease in tumor volume or the appearance of new lesions.
CA 125 was used to follow disease when two separate
values were )100 U/mL at least 24 hours apart. The
status of each patient was recorded as alive without dis-
ease, alive with disease, dead of disease, or dead of other
causes.
Results
Forty patients with refractory gynecologic malignancies were
treated with a total of 182 cycles of cyclosporin A in combi-
nation with platinum, Taxol, or etoposide chemotherapy.
Demographic characteristics are listed in Table 1. Most
( )patients in this study had recurrent ovarian cancer 72% .
( )Other cancers included were uterine cancer 18% , cervical
( ) ( )cancer 8% , and choriocarcinoma 2% . All patients had
been heavily pretreated; 82% of patients had received two
or more chemotherapy regimens previously with a mean of
2.8 regimens.
Table 1. Clinicopathologic Characteristics of Patients Treated with Cy-
closporin A.
( )Mean age years 55.8
Parity
Nulliparous 8
Primiparous 5
Multiparous 27
Cancer type
Ovary 29
Uterus 7
Cervix 3
Choriocarcinoma 1
Previous chemotherapy
( )No. regimens
1 7
2 7
3 15
4 7
5 4
Mean 2.8
Resistance
Platinum 39
Taxol 21
Adriamycin 4
Ifosfamide 1
Etoposide 2
All patients showed chemoresistance to the chemothera-
peutic agent that was given in conjunction with cyclosporin
A. Ninety-seven percent of the patients showed resistance
to platinum agents, and 52% also showed resistance to
(Taxol. All patients had measurable disease. Two patients
) ( )were followed with CA125 only. Twenty-seven 70% of the
patients received three or more courses of cyclosporin A–
based chemotherapy. Ten patients received only two
courses because of progression despite cyclosporin A–
based chemotherapy. Patients were considered evaluable if
they survived 28 days after treatment with cyclosporin A–
based chemotherapy. Thirty-eight of the 40 patients were
evaluable. Eighty-eight percent received platinum alone in
conjunction with cyclosporin A, and 8% received Taxol
( ) ( )Table 2 . Twenty-six 65% of all patients received three or
more cycles of cyclosporin A–based treatment. Two pa-
tients were treated with two chemotherapy agents with
( )cyclosporin A Table 2 .
Because response rates may vary with tumor type, re-
(sults were analyzed separately for this characteristic Table
)3 . The distribution of response to chemotherapy with cy-
closporin A is presented in Table 4. Table 4 is structured
based on the time interval between the chemotherapy agent
plus cyclosporin A and the previous use of the same agent.
Among the 29 patients with ovarian cancer, 28 were evalu-
able. There was a 25% response rate, with three complete
and four partial responses. The duration of response ranged
from 5.2 to 27 months, with a median duration of 6.8
months. Two patients with ovarian cancer were followed
solely on the basis of their CA 125 levels. One of these
patients had progression during treatment with platinum for
recurrent ovarian cancer. She underwent secondary optimal
cytoreduction, followed by six cycles of cyclosporin A and
carboplatin chemotherapy. The CA 125 level declined from
178 to 32 U/mL and the patient remains disease free after
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Table 2. Treatment Characteristics of Patients Receiving Cyclosporin A.
No. of Patients
Number of treatment
courses with CSA
1 2
2 10
G3 28
Associated chemotherapy
Agents
Platinum 35
Taxol 3
Taxol/platinum 1
Etoposide/platinum 1
( )CSA, cyclosporin A .
2.3 years. The second patient had a partial response, and
her CA 125 levels declined from 1969 to 753 U/mL after
four cycles. She completed six total cycles and died 6
months later with progressive disease.
To further define drug resistance, the data were analyzed
based on the time period between relapse or progression
and start of the same chemotherapy agent with cyclosporin
A. Table 4 presents patients with ovarian cancer. Among
( )the responders CR or PR , 71% progressed while on
chemotherapy, and cyclosporin A was added to their
chemotherapy regimen. Among patients who had disease
( )progression during treatment with the agent, 5 of 11 45%
had a response with the addition of cyclosporin A. In con-
trast, 17 patients had recurrence within 6 months of previ-
( )ous chemotherapy, and only 2 patients 12% had a
response with the addition of cyclosporin A. The differ-
ence between these groups was not statistically significant
( )Ps .08 .
There were six available patients with uterine cancer,
and three of these showed a complete response, for a 50%
response rate. The median duration of response was 11
months, with a range of 5 to 23 months. Among the respon-
ders, two patients had recurrent papillary serous endome-
trial carcinoma and the third patient had endometroid
adenocarcinoma.
There were no responders among the three patients with
cervical cancer. All patients with cervical cancer had squa-
mous lesions. One progressed on initial cisplatin-based
Table 3. Patient Response to Cyclosporin A–Based Chemotherapy.
Cancer type Complete Partial Stable Progression Not
response response evaluable
Ovary
Serous 3 2 9 9 1
Other - 2 1 2 -
Uterus
Papillary serous 2 - - - -
Sarcoma - - 1 - 1
Endometroid 1 - - 2 -
Cervix
Squamous - - - 3 -
Choriocarcinoma 1 - - - -
Total 7 4 11 16 2
Table 4. Distribution of Response to Chemotherapy with Cyclosporin A
Based on Time from Development of Resistance for Patients with
Ovarian Cancer.
a( )Patient no. Time mo Chemotherapy Response
3 0 Carboplatin CR
35 0 Carboplatin CR
7 0 Taxol PR
24 0 Cisplatin PR
38 0 Carboplatin PR
26 0 Taxol/Carboplatin Stable
30 0 Cisplatin Stable
10 0 Cisplatin Progression
19 0 Carboplatin Progression
32 0 Cisplatin Progression
6 0 Cisplatin Progression
14 2 Carboplatin Stable
11 2 Carboplatin Progression
29 2 Cisplatin Not evaluable
16 3 Carboplatin Stable
31 3 Carboplatin Stable
27 3 Cisplatin Progression
17 4 Taxol Stable
4 4 Carboplatin Stable
34 4 Cisplatin Stable
22 5 Cisplatin CR
40 5 Carboplatin Stable
2 5 Carboplatin Progression
5 5 Carboplatin Progression
33 5 Carboplatin Progression
8 6 Carboplatin PR
37 6 Cisplatin Stable
36 6 Cisplatin Progression
39 6 Carboplatin Progression
aInterval between chemotherapy agentqcyclosporin A and the previous
use of the same agent. Time 0 represents addition of cyclosporin A after
(progression while on the same chemotherapy drug. CR, complete
)response; PR, partial response .
chemotherapy, and cyclosporin A was added to the chemo-
therapy regimen. The other two developed a recurrence in a
previously radiated field. Both of these patients had progres-
sive disease despite cisplatin chemotherapy, and cy-
closporin A was added in an attempt to modulate chemore-
sistance. One patient with choriocarcinoma had failed multi-
ple chemotherapy regimens but had a complete response to
Table 5. Distribution of Response to Chemotherapy with Cyclosporin A
Based on Time from Development of Resistance for Patients with
Gynecologic Malignancies.
Patient Time Chemotherapy Response Cancer type
a( )no. months
15 0 Cisplatin Progression Cervix
20 0 Cisplatin Progression Cervix
21 0 Cisplatin Progression Cervix
25 0 Etoposide/ CR Choriocarcinoma
Cisplatin
1 0 Cisplatin CR Uterus
13 0 Taxol CR Uterus
28 0 Cisplatin CR Uterus
9 0 Cisplatin Stable Uterus
23 0 Carboplatin Progression Uterus
12 5 Carboplatin Progression Uterus
18 0 Cisplatin Not evaluable Uterus
aInterval between chemotherapy agentqcyclosporin A and the previous
use of the same agent. Time 0 represents addition of cyclosporin A after
(progression while on the same chemotherapy drug. CR, complete
)response; PR, partial response .
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Table 6. Adverse Effects with Cyclosporin A–Based Chemotherapy.
Adverse effect Patients with grade Patients with grade
( ) ( )1 or 2 response % 3 or 4 response %
( ) ( )Leukopenia 10 25 6 15
( ) ( )Thrombocytopenia 8 20 9 22
( ) ( )Anemia 8 20 3 8
( ) ( )Nausea 15 38 1 2
( ) ( )Vomiting 7 18 1 2
( ) ( )Diarrhea 1 2 0 0
( ) ( )Renal 0 0 1 2
( ) ( )Neurological 1 2 1 2
( ) ( )Flushing 10 25 0 0
etoposide and cisplatin given with cyclosporin A. The re-
sponse lasted for 3 months. Overall, among the 38 available
patients with gynecologic malignancies, a 29% objective
( )response rate 18% complete, 11% partial was observed.
Table 5 presents patients with other gynecologic malig-
nancies and the time period between relapse or progression
and start of the same chemotherapy agent with cyclosporin
A. All three patients with uterine cancer who had a complete
response had progressive disease while on the same
chemotherapy agent used with cyclosporin A.
All patients were available for toxicity, and the rates for
each toxic reaction are reported in Table 6. Hematologic
toxicity was common. Grade 3 or 4 leukopenia was present
in 15% and grade 3 or 4 thrombocytopenia in 22%. In most
cases the toxicity was transient, and only three patients
(required a treatment delay 1 week for two patients and 2
)weeks for one patient . G-CSF was used in 18 patients
( ) ( )45% per ASCO guidelines. Mild grade 1 or 2 gastrointes-
tinal toxicity was commonly observed; however, severe
( )grade 3 or 4 nausea or vomiting was rare. Ondansetron
was effectively used as a part of the standard premedication
regimen, resulting in minimal severe gastrointestinal toxicity.
Renal toxicity was uncommon, and only one patient had
grade 3 renal toxicity. In this patient the serum creatinine
( )increased to 3.8, and the chemotherapy carboplatin was
stopped. Neurological toxicity was also uncommon, but va-
( )somotor flushing occurred in 10 25% patients.
Discussion
Chemotherapeutic resistance continues to be a significant
obstacle to treatment of gynecologic malignancies. This is
especially true for epithelial ovarian carcinoma, for which
initial response rates are often greater than 80%. Unfortu-
nately, the long-term survival for advanced stage disease
does not reach 50% at 5 years. The MDR gene and its
product, P-glycoprotein, have been shown to play a role in
[ ]resistance to chemotherapeutic agents 15 . This appears to
be the dominant mechanism for resistance in many chemo-
therapy agents including etoposide, vincristine, doxorubicin,
daunorubicin, and paclitaxel. Cyclosporin A has been shown
to reverse MDR and to reduce chemotherapeutic resistance
[ ]and cross resistance in vitro to all of these agents 16-17 .
The mechanisms for platinum resistance appear to be
different than MDR and may include enhanced DNA repair,
increased intracellular levels of glutathione or metalloth-
ionein, or increased expression of enzymes responsible for
[ ]the regulation of DNA repair 18 . Cyclosporin A has also
been shown to have the ability to reverse platinum resis-
[ ]tance 19 . Recently, several studies have evaluated poten-
tial molecular mechanisms underlying resistance reversal.
Kashani-Sabet and colleagues have shown that administra-
tion of cyclosporin A to cisplatin-resistant epithelial ovarian
cancer cells reduces levels of the c-fos gene product, which
was found to be elevated in the resistant cell line and
induced in the cisplatin-sensitive line by administration of
[ ]cisplatin 20 . The reduction of c-fos gene product was
followed by a reduction in thymidylate synthase and DNA
polymerase beta, which plays a role in DNA synthesis and
[ ]repair 20 . The reduction in levels of these enzymes corre-
sponds with restoration of platinum sensitivity. As a corol-
lary, in vitro induction of platinum resistance is often accom-
panied by elevation of these enzymes. Further support for
the important role of c-fos in platinum-resistant cancer
comes from the observation that ribozyme-mediated cleav-
age of c-fos mRNA effects reversal of platinum resistance
and concomitant reduced expression of DNA polymerase II
[ ]and metallothionein mRNA 18 . Ribozyme-mediated rever-
sal of chemoresistance in a multiple drug resistant cell line
by directing the ribozyme against the p-glycoprotein mRNA
has also been used as a strategy to reverse drug resistance
[ ]21 . These studies provide a logical model of resistance
reversal by cyclosporin A on which to base clinical studies.
The effectiveness of cyclosporin A in reversal of chemo-
( )resistance may be dependent on tumor type Table 7 .
Trials of cyclosporin A in renal carcinoma have shown
[ ]dismal results 22,23 . However, cyclosporin A appears to
[ ]be highly effective in treatment of acute leukemia 24 .
Clinical studies of cyclosporin A in gynecologic malignan-
cies are limited. The phase I study of cyclosporin A with
platinum in advanced gynecologic malignancies performed
by the GOG established a tolerable dose regimen and
[ ]reported a total response rate of 25% 9 . Similarly, Cham-
bers, and colleagues reported an overall 24% response rate
[ ]in ovarian and fallopian tube malignancies 11 . However, in
the recently reported phase II trial by the GOG, only a 12%
[ ]response was found 25 . In the present study, evaluable
Table 7. Response Rates to Cyclosporin A–Based Treatment Regimens.
Author Tumor type Evaluable Chemotherapy Complete Partial
( ) ( ) ( )patients n response n response n
[ ]Rodenberg et al. 22 Renal 15 Vinblastine - -
[ ]Verweij et al. 23 Renal 10 Vinblastine - -
Colorectal 23 Epirubicin - 1
[ ]List et al. 24 Acute leukemia 33 Cytarabineq daunomycin 20 2
[ ]Chambers et al. 11 Ovarian 38 Carboplatin 1 8
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patients with chemorefractory ovarian cancer had a 25%
response rate. Patients with uterine cancer responded even
better, with a 50% response rate. Unfortunately, no re-
sponses were seen in women with cervical malignancies.
Cyclosporin A was well tolerated. The major nonhemato-
logic toxic reaction was nausea; however, severe nausea or
vomiting was avoided by the use of effective antiemetics
such as ondansetron in most cases. Even though many
patients had grade 3 or 4 hematologic toxicity, this was
transient, and treatment delays were needed only in a small
fraction of patients. It has been shown that most hemato-
logic toxicity is more likely due to the chemotherapy rather
[ ]than cyclosporin 11 . The GOG study reported grade 4
( )nephrotoxicity in 4 of 20 patients 20% in the phase I trial
[ ]9 . However, no renal toxicity was observed in subsequent
[ ]studies 10,25 . In the present study renal toxicity was
minimal. Even among heavily pretreated patients, hemato-
logic toxicity was not significantly different from other stud-
ies.
A recent article by Hojo et al. has raised concerns that
prolonged treatment with cyclosporin A may promote cancer
progression mediated by induction of transforming growth
[ ]factor-b 26 . Although this finding would be a concern in
patients who have prolonged exposure to cyclosporin A
alone, it does not seem to apply to the patients treated in
combination with chemotherapy. In addition, the patients
treated in this study received cyclosporin A only for a short
duration to modify chemoresistance.
Due to potential concerns of hepatic and renal toxicity as
well as for the potent immunosuppressive properties of
cyclosporin A, cyclosporin analogues have been developed
with fewer immunosuppressive properties and improved or
similar resistance-reverting potential. PSC833 appears to
be more potent than cyclosporin A with minimal immuno-
[ ]suppressive properties 27-29 . This agent is currently under
investigation in several clinical trials. Our data suggest that
cyclosporin A or possibly its analogues should be studied in
less heavily treated patients. In addition, these agents ap-
pear promising for treatment of recurrent uterine cancer and
should be investigated further.
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